Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics
Antibody-drug conjugates: Converting our expanding knowledge of disease and immune system biology into successful immunotherapeutics
Antibody-drug conjugates, or ADCs, are a class of exciting new therapeutics that utilize the patient’s own immune system, with the antibody delivering the drug right to the disease site
There are two ADCs currently being used to treat lymphoma and breast cancer in patients, with dozens more in clinical development. Yet challenges remain, and new tools and methods must be designed to deal with them.
This white paper discusses:
- Early clinical failures of ADCs and what was learned from those failures
- Selecting the tumor antigen target in ADC development
- How monoclonal antibodies serve as vehicles to deliver a drug to the disease site
Read the white paper.
To access the complimentary white paper 'Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics', please fill in the form below.
By submitting this form you also agree to receive information relevant to your interests from Elsevier B.V. and its affiliates worldwide. You can opt-out at any time by following the instructions given in the email messages you receive.
Elsevier's R&D Solutions supporting 'Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics'
Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert